Enanta Pharmaceuticals Stock Shares Outstanding
| ENTA Stock | USD 13.91 0.35 2.58% |
Enanta Pharmaceuticals fundamentals help investors to digest information that contributes to Enanta Pharmaceuticals' financial success or failures. It also enables traders to predict the movement of Enanta Stock. The fundamental analysis module provides a way to measure Enanta Pharmaceuticals' intrinsic value by examining its available economic and financial indicators, including the cash flow records, the balance sheet account changes, the income statement patterns, and various microeconomic indicators and financial ratios related to Enanta Pharmaceuticals stock.
As of May 3, 2024, Common Stock Shares Outstanding is expected to decline to about 18 M. Enanta | Shares Outstanding |
Enanta Pharmaceuticals Company Shares Outstanding Analysis
Enanta Pharmaceuticals' Outstanding Shares are shares of common stock of a public company that were purchased by investors after they were authorized and issued by the company to the public. Outstanding Shares are typically reported on fully diluted basis, including exotic instruments such as options, or convertibles bonds.
Current Enanta Pharmaceuticals Shares Outstanding | 21.16 M |
Most of Enanta Pharmaceuticals' fundamental indicators, such as Shares Outstanding, are part of a valuation analysis module that helps investors searching for stocks that are currently trading at higher or lower prices than their real value. If the real value is higher than the market price, Enanta Pharmaceuticals is considered to be undervalued, and we provide a buy recommendation. Otherwise, we render a sell signal.
Enanta Shares Outstanding Driver Correlations
Understanding the fundamental principles of building solid financial models for Enanta Pharmaceuticals is extremely important. It helps to project a fair market value of Enanta Stock properly, considering its historical fundamentals such as Shares Outstanding. Since Enanta Pharmaceuticals' main accounts across its financial reports are all linked and dependent on each other, it is essential to analyze all possible correlations between related accounts. However, instead of reviewing all of Enanta Pharmaceuticals' historical financial statements, investors can examine the correlated drivers to determine its overall health. This can be effectively done using a conventional correlation matrix of Enanta Pharmaceuticals' interrelated accounts and indicators.
Click cells to compare fundamentals
Enanta Shares Outstanding Historical Pattern
Today, most investors in Enanta Pharmaceuticals Stock are looking for potential investment opportunities by analyzing not only static indicators but also various Enanta Pharmaceuticals' growth ratios. Consistent increases or drops in fundamental ratios usually indicate a possible pattern that can be successfully translated into profits. However, when comparing two companies, knowing each company's shares outstanding growth rates may not be enough to decide which company is a better investment. That's why investors frequently use a static breakdown of Enanta Pharmaceuticals shares outstanding as a starting point in their analysis.
Enanta Pharmaceuticals Shares Outstanding |
| Timeline |
Outstanding shares that are stated on company Balance Sheet are used when calculating many important valuation and performance indicators including Return on Equity, Market Cap, EPS and many others.
| Competition |
Enanta Common Stock Shares Outstanding
Common Stock Shares Outstanding |
|
Based on the latest financial disclosure, Enanta Pharmaceuticals has 21.16 M of shares currently outstending. This is 88.28% lower than that of the Biotechnology sector and 80.2% lower than that of the Health Care industry. The shares outstanding for all United States stocks is 96.3% higher than that of the company.
Enanta Shares Outstanding Peer Comparison
Stock peer comparison is one of the most widely used and accepted methods of equity analyses. It analyses Enanta Pharmaceuticals' direct or indirect competition against its Shares Outstanding to detect undervalued stocks with similar characteristics or determine the stocks which would be a good addition to a portfolio. Peer analysis of Enanta Pharmaceuticals could also be used in its relative valuation, which is a method of valuing Enanta Pharmaceuticals by comparing valuation metrics of similar companies.Enanta Pharmaceuticals is currently under evaluation in shares outstanding category among related companies.
Enanta Fundamentals
| Return On Equity | -0.56 | ||||
| Return On Asset | -0.23 | ||||
| Profit Margin | (1.88) % | ||||
| Operating Margin | (1.94) % | ||||
| Current Valuation | 164.76 M | ||||
| Shares Outstanding | 21.16 M | ||||
| Shares Owned By Insiders | 6.00 % | ||||
| Shares Owned By Institutions | 94.00 % | ||||
| Number Of Shares Shorted | 2.74 M | ||||
| Price To Earning | 366.13 X | ||||
| Price To Book | 1.81 X | ||||
| Price To Sales | 4.73 X | ||||
| Revenue | 79.2 M | ||||
| Gross Profit | 86.16 M | ||||
| EBITDA | (123.48 M) | ||||
| Net Income | (133.82 M) | ||||
| Cash And Equivalents | 253.29 M | ||||
| Cash Per Share | 12.22 X | ||||
| Total Debt | 26.51 M | ||||
| Debt To Equity | 0.08 % | ||||
| Current Ratio | 13.59 X | ||||
| Book Value Per Share | 9.07 X | ||||
| Cash Flow From Operations | (103.15 M) | ||||
| Short Ratio | 11.01 X | ||||
| Earnings Per Share | (6.57) X | ||||
| Target Price | 22.29 | ||||
| Number Of Employees | 145 | ||||
| Beta | 0.49 | ||||
| Market Capitalization | 286.88 M | ||||
| Total Asset | 462.27 M | ||||
| Retained Earnings | (207 M) | ||||
| Working Capital | 360 M | ||||
| Current Asset | 241.79 M | ||||
| Current Liabilities | 9.57 M | ||||
| Net Asset | 462.27 M |
About Enanta Pharmaceuticals Fundamental Analysis
The Macroaxis Fundamental Analysis modules help investors analyze Enanta Pharmaceuticals's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Enanta Pharmaceuticals using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Enanta Pharmaceuticals based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.
Pair Trading with Enanta Pharmaceuticals
One of the main advantages of trading using pair correlations is that every trade hedges away some risk. Because there are two separate transactions required, even if Enanta Pharmaceuticals position performs unexpectedly, the other equity can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Enanta Pharmaceuticals will appreciate offsetting losses from the drop in the long position's value.Moving together with Enanta Stock
| 0.71 | VKTX | Viking Therapeutics | PairCorr |
| 0.7 | DYAI | Dyadic International Financial Report 8th of May 2024 | PairCorr |
Moving against Enanta Stock
| 0.52 | OVID | Ovid Therapeutics | PairCorr |
| 0.43 | LFCR | Lifecore Biomedical Financial Report 6th of June 2024 | PairCorr |
| 0.42 | ORGO | Organogenesis Holdings Earnings Call This Week | PairCorr |
| 0.41 | GNLX | Genelux Common | PairCorr |
The ability to find closely correlated positions to Enanta Pharmaceuticals could be a great tool in your tax-loss harvesting strategies, allowing investors a quick way to find a similar-enough asset to replace Enanta Pharmaceuticals when you sell it. If you don't do this, your portfolio allocation will be skewed against your target asset allocation. So, investors can't just sell and buy back Enanta Pharmaceuticals - that would be a violation of the tax code under the "wash sale" rule, and this is why you need to find a similar enough asset and use the proceeds from selling Enanta Pharmaceuticals to buy it.
The correlation of Enanta Pharmaceuticals is a statistical measure of how it moves in relation to other instruments. This measure is expressed in what is known as the correlation coefficient, which ranges between -1 and +1. A perfect positive correlation (i.e., a correlation coefficient of +1) implies that as Enanta Pharmaceuticals moves, either up or down, the other security will move in the same direction. Alternatively, perfect negative correlation means that if Enanta Pharmaceuticals moves in either direction, the perfectly negatively correlated security will move in the opposite direction. If the correlation is 0, the equities are not correlated; they are entirely random. A correlation greater than 0.8 is generally described as strong, whereas a correlation less than 0.5 is generally considered weak.
Correlation analysis and pair trading evaluation for Enanta Pharmaceuticals can also be used as hedging techniques within a particular sector or industry or even over random equities to generate a better risk-adjusted return on your portfolios.Check out Enanta Pharmaceuticals Piotroski F Score and Enanta Pharmaceuticals Altman Z Score analysis. For information on how to trade Enanta Stock refer to our How to Trade Enanta Stock guide.You can also try the Correlation Analysis module to reduce portfolio risk simply by holding instruments which are not perfectly correlated.
Complementary Tools for Enanta Stock analysis
When running Enanta Pharmaceuticals' price analysis, check to measure Enanta Pharmaceuticals' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Enanta Pharmaceuticals is operating at the current time. Most of Enanta Pharmaceuticals' value examination focuses on studying past and present price action to predict the probability of Enanta Pharmaceuticals' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Enanta Pharmaceuticals' price. Additionally, you may evaluate how the addition of Enanta Pharmaceuticals to your portfolios can decrease your overall portfolio volatility.
| Odds Of Bankruptcy Get analysis of equity chance of financial distress in the next 2 years | |
| Cryptocurrency Center Build and monitor diversified portfolio of extremely risky digital assets and cryptocurrency | |
| Content Syndication Quickly integrate customizable finance content to your own investment portal | |
| Portfolio Volatility Check portfolio volatility and analyze historical return density to properly model market risk | |
| Bollinger Bands Use Bollinger Bands indicator to analyze target price for a given investing horizon | |
| Performance Analysis Check effects of mean-variance optimization against your current asset allocation | |
| Investing Opportunities Build portfolios using our predefined set of ideas and optimize them against your investing preferences | |
| Correlation Analysis Reduce portfolio risk simply by holding instruments which are not perfectly correlated | |
| Crypto Correlations Use cryptocurrency correlation module to diversify your cryptocurrency portfolio across multiple coins | |
| Sync Your Broker Sync your existing holdings, watchlists, positions or portfolios from thousands of online brokerage services, banks, investment account aggregators and robo-advisors. |
Is Enanta Pharmaceuticals' industry expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Enanta Pharmaceuticals. If investors know Enanta will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Enanta Pharmaceuticals listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Quarterly Earnings Growth (0.66) | Earnings Share (6.57) | Revenue Per Share 3.5 | Quarterly Revenue Growth (0.24) | Return On Assets (0.23) |
The market value of Enanta Pharmaceuticals is measured differently than its book value, which is the value of Enanta that is recorded on the company's balance sheet. Investors also form their own opinion of Enanta Pharmaceuticals' value that differs from its market value or its book value, called intrinsic value, which is Enanta Pharmaceuticals' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Enanta Pharmaceuticals' market value can be influenced by many factors that don't directly affect Enanta Pharmaceuticals' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Enanta Pharmaceuticals' value and its price as these two are different measures arrived at by different means. Investors typically determine if Enanta Pharmaceuticals is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Enanta Pharmaceuticals' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.